江苏威奇达药业有限公司简介
江苏威奇达药业有限公司（原名上海现代制药海门有限公司）为中国医药集团旗下化学制药工业平台上海现代制药股份有限公司（股票代码600420）的下属公司，于2010年2月在江苏省南通市成立，注册资本8亿元人民币。公司定位为高端、特色原料药研发生产基地，主要产品涵盖抗感染类、内分泌类、心脑血管类、抗肿瘤类、抗抑郁类、大健康类等领域，远销国际市场，涵盖20多个国家和地区。公司致力于成为专业、服务、创新、可靠的制药服务平台。通过多年的沉淀，拥有完备的生产技术能力、完善的质量管理、EHS管理体系，为全球客户提供从中试放大到商业化生产的核心服务和各种认证注册申报支持。公司已先后通过NMPA、FDA、WHO等权威认证，为全球知名药企长期提供服务。
公司设有研发/技术中心，依托中国医药集团旗下中国医药工业研究总院，拥有强大的研发技术、专业的人才团队和先进的设备仪器。已通过国家知识产权管理认证，且为“江苏省高新技术企业”，先后被认定为 “江苏省高端原料药合成工程技术研究中心”、“江苏省企业技术中心”、“江苏省医药行业诚信企业”。阿奇霉素、L-α-甘油磷酰胆碱、盐酸奈必洛尔产品获得高新技术产品认证。依托公司技术队伍和质量体系，我们有能力和经验，开展高技术含量、高附加值、低排放的CMO&CDMO服务。
公司主要产品包括：
阿奇霉素、L-α-甘油磷酰胆碱、盐酸奈必洛尔、硫酸阿巴卡韦、硫酸阿扎那韦、紫檀芪、白藜芦醇、氧化白藜芦醇、硫辛酸、甲基门冬氨酸 咖啡酸苯乙酯、二香草基四氢呋喃、钆布醇。
Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Shyndec Pharmaceutical Haimen Co., Ltd.) is the third subsidiary of Shanghai Shyndec Pharmaceutical Co., Ltd. (stock code: 600420), a chemical and pharmaceutical industry platform under China National Pharmaceutical Group Co., Ltd. (Sinopharm). It is the wholly-owned subsidiary of Sinopharm Weiqida Pharmaceutical Co., Ltd. Jiangsu Weiqida was established in Nantong City, Jiangsu Province in February 2010 with a registered capital of 800 million yuan. The company is positioned as an exclusive high-end and characteristic API R&D and production base. Its main products cover antiviral, anti-infective, cardiovascular and cerebrovascular, and general health fields, and are exported to the international market, covering more than 20 countries and regions. It has a high market share. The company is committed to become a professional, service, innovative and reliable pharmaceutical service platform. “All for health, Health for all”. Through years of precipitation, we have complete production technology capabilities, perfect quality management, and EHS management systems, providing core services from pilot scale-up to commercial production and various certification, registration support to global customers. We have successively passed NMPA, FDA, WHO and other authoritative certifications, and have provided long-term services for world-renowned pharmaceutical companies.
Jiangsu Weiqida has a R&D/technology center, relying on the China State Institute of Pharmaceutical Industry under the China National Pharmaceutical Group, with strong R&D technology, professional talent team and advanced equipment. It has passed the national intellectual property management certification, and is certificated as “Jiangsu High-tech Enterprise”. It has been successively recognized as “Jiangsu High-end API Synthesis Engineering Technology Research Center”, “Jiangsu Enterprise Technology Center”, and “Jiangsu Pharmaceutical Industry Integrity Enterprise”. Azithromycin, L-α-Glycerophosphoryl Choline, and Nebivolol Hydrochloride were certified as high-tech products. In the future, the company will actively promote R&D innovation, focusing on the development of high-tech, high value-added, low-emission featured products, and building the company into a CDMO customized processing industry base.